<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Cannabinoids for fibromyalgia - Walitt, B - 2016 | Cochrane Library</title> <meta content="Cannabinoids for fibromyalgia - Walitt, B - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011694.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Cannabinoids for fibromyalgia - Walitt, B - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011694.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011694.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Cannabinoids for fibromyalgia" name="citation_title"/> <meta content="Brian Walitt" name="citation_author"/> <meta content="National Institutes of Health" name="citation_author_institution"/> <meta content="Petra Klose" name="citation_author"/> <meta content="University of Duisburg-Essen" name="citation_author_institution"/> <meta content="Mary-Ann Fitzcharles" name="citation_author"/> <meta content="Montreal General Hospital, McGill University Health Centre" name="citation_author_institution"/> <meta content="Tudor Phillips" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Winfried Häuser" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="whaeuser@klinikum-saarbruecken.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD011694.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/07/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011694.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011694.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011694.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amitriptyline [therapeutic use]; Analgesics, Non-Narcotic [therapeutic use]; Cannabinoids [adverse effects, *therapeutic use]; Dronabinol [adverse effects, *analogs &amp; derivatives, therapeutic use]; Fibromyalgia [*drug therapy]; Health Status; *Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011694.pub2&amp;doi=10.1002/14651858.CD011694.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="23LRTUA6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011694\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011694\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","fa","fr","es","de","ru","ms","hr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011694.pub2",title:"Cannabinoids for fibromyalgia",firstPublishedDate:"Jul 18, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011694.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011694.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011694.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011694.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011694.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011694.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011694.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011694.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011694.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011694.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13157 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011694.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/full#CD011694-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/full#CD011694-sec-0059"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/full#CD011694-sec-0008"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/full#CD011694-sec-0013"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/full#CD011694-sec-0014"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/full#CD011694-sec-0037"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/full#CD011694-sec-0053"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/appendices#CD011694-sec-0071"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Cannabinoids for fibromyalgia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/information#CD011694-cr-0004">Brian Walitt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/information#CD011694-cr-0005">Petra Klose</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/information#CD011694-cr-0006">Mary-Ann Fitzcharles</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/information#CD011694-cr-0007">Tudor Phillips</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011694.pub2/information#CD011694-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Winfried Häuser</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/information/en#CD011694-sec-0082">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 July 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011694.pub2">https://doi.org/10.1002/14651858.CD011694.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011694-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011694-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011694-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011694-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011694-abs-0010">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011694-abs-0001" lang="en"> <section id="CD011694-sec-0001"> <h3 class="title" id="CD011694-sec-0001">Background</h3> <p>This review is one of a series on drugs used to treat fibromyalgia. Fibromyalgia is a clinically well‐defined chronic condition of unknown aetiology characterised by chronic widespread pain that often co‐exists with sleep problems and fatigue affecting approximately 2% of the general population. People often report high disability levels and poor health‐related quality of life (HRQoL). Drug therapy focuses on reducing key symptoms and disability, and improving HRQoL. Cannabis has been used for millennia to reduce pain and other somatic and psychological symptoms. </p> </section> <section id="CD011694-sec-0002"> <h3 class="title" id="CD011694-sec-0002">Objectives</h3> <p>To assess the efficacy, tolerability and safety of cannabinoids for fibromyalgia symptoms in adults. </p> </section> <section id="CD011694-sec-0003"> <h3 class="title" id="CD011694-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE to April 2016, together with reference lists of retrieved papers and reviews, three clinical trial registries, and contact with trial authors. </p> </section> <section id="CD011694-sec-0004"> <h3 class="title" id="CD011694-sec-0004">Selection criteria</h3> <p>We selected randomised controlled trials of at least four weeks' duration of any formulation of cannabis products used for the treatment of adults with fibromyalgia. </p> </section> <section id="CD011694-sec-0005"> <h3 class="title" id="CD011694-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted the data of all included studies and assessed risk of bias. We resolved discrepancies by discussion. We performed analysis using three tiers of evidence. First tier evidence was derived from data meeting current best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention‐to‐treat analysis without imputation for drop‐outs; at least 200 participants in the comparison, eight to 12 weeks' duration, parallel design), second tier evidence from data that did not meet one or more of these criteria and were considered at some risk of bias but with adequate numbers (i.e. data from at least 200 participants) in the comparison, and third tier evidence from data involving small numbers of participants that were considered very likely to be biased or used outcomes of limited clinical utility, or both. We assessed the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation). </p> </section> <section id="CD011694-sec-0006"> <h3 class="title" id="CD011694-sec-0006">Main results</h3> <p>We included two studies with 72 participants. Overall, the two studies were at moderate risk of bias. The evidence was derived from group mean data and completer analysis (very low quality evidence overall). We rated the quality of all outcomes according to GRADE as very low due to indirectness, imprecision and potential reporting bias. </p> <p>The primary outcomes in our review were participant‐reported pain relief of 50% or greater, Patient Global Impression of Change (PGIC) much or very much improved, withdrawal due to adverse events (tolerability) and serious adverse events (safety). Nabilone was compared to placebo and to amitriptyline in one study each. Study sizes were 32 and 40 participants. One study used a cross‐over design and one used a parallel group design; study duration was four or six weeks. Both studies used nabilone, a synthetic cannabinoid, with a bedtime dosage of 1 mg/day. No study reported the proportion of participants experiencing at least 30% or 50% pain relief or who were very much improved. No study provided first or second tier (high to moderate quality) evidence for an outcome of efficacy, tolerability and safety. Third tier (very low quality) evidence indicated greater reduction of pain and limitations of HRQoL compared to placebo in one study. There were no significant differences to placebo noted for fatigue and depression (very low quality evidence). Third tier evidence indicated better effects of nabilone on sleep than amitriptyline (very low quality evidence). There were no significant differences between the two drugs noted for pain, mood and HRQoL (very low quality evidence). More participants dropped out due to adverse events in the nabilone groups (4/52 participants) than in the control groups (1/20 in placebo and 0/32 in amitriptyline group). The most frequent adverse events were dizziness, nausea, dry mouth and drowsiness (six participants with nabilone). Neither study reported serious adverse events during the period of both studies. We planned to create a GRADE 'Summary of findings' table, but due to the scarcity of data we were unable to do this. We found no relevant study with herbal cannabis, plant‐based cannabinoids or synthetic cannabinoids other than nabilone in fibromyalgia. </p> </section> <section id="CD011694-sec-0007"> <h3 class="title" id="CD011694-sec-0007">Authors' conclusions</h3> <p>We found no convincing, unbiased, high quality evidence suggesting that nabilone is of value in treating people with fibromyalgia. The tolerability of nabilone was low in people with fibromyalgia. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011694-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011694-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011694-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011694-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011694-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011694-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011694-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011694-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011694-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011694-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011694-abs-0002" lang="en"> <h3>Cannabis products for people with fibromyalgia</h3> <p><b>Background</b> </p> <p>Fibromyalgia is characterised by chronic (longer than three months) widespread pain that often co‐exists with sleep problems, problems with thinking and fatigue (exhaustion). People often report severe limitations of daily functioning and poor health‐related quality of life. Therapies focus on reducing key symptoms and disability, and improving health‐related quality of life. Cannabis has been used for 3000 years to reduce pain and other symptoms, such as loss of appetite and anxiety. </p> <p><b>Key results and quality of the evidence</b> </p> <p>In April 2016 we searched for reports of clinical trials that used cannabis products to treat symptoms in adults with fibromyalgia. We found two small, moderate quality studies, of four and six weeks long, including 72 participants. Both studies tested nabilone, a synthetic (man‐made) cannabis product, comparing it with placebo (a dummy pill) or amitriptyline (an antidepressant frequently used in the treatment of fibromyalgia). </p> <p>Nabilone did not convincingly relieve fibromyalgia symptoms (pain, sleep, fatigue) better than placebo or amitriptyline (very low quality evidence). Compared with placebo and amitriptyline, more people experienced side effects and left the study due to side effects (very low quality evidence). There were no serious side effects reported. We found no relevant study with herbal cannabis, plant‐based cannabinoids or other synthetic cannabinoids than nabilone in fibromyalgia. </p> <p>There was not enough high quality evidence available to draw any robust conclusions. We found no studies on medical cannabis in fibromyalgia. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011694-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011694-sec-0059"></div> <h3 class="title" id="CD011694-sec-0060">Implications for practice</h3> <section id="CD011694-sec-0060"> <section id="CD011694-sec-0061"> <h5 class="title">For people with fibromyalgia</h5> <p>Clinical trial evidence on the use of cannabis products in fibromyalgia was limited to two small studies with short‐term duration. No convincing, unbiased evidence suggests that nabilone is of value in treating people with fibromyalgia. The tolerability of nabilone was low in people with fibromyalgia. Adverse events (particularly somnolence, dizziness, vertigo) may limit its clinical usefulness. We found no relevant study with herbal cannabis, plant‐based cannabinoids or other synthetic cannabinoids than nabilone in fibromyalgia. </p> </section> <section id="CD011694-sec-0062"> <h5 class="title">For physicians</h5> <p>Herbal, plant‐based and synthetic cannabis products are not licensed for fibromyalgia in any country. Other than one weak recommendation from a trial of a pharmacological cannabinoid preparation in people with fibromyalgia in the setting of important sleep disturbance in the Canadian fibromyalgia guidelines (<a href="./references#CD011694-bbs2-0016" title="FitzcharlesMA , Ste-MariePA , GoldenbergDL , PereiraJX , AbbeyS , ChoinièreM , et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Research &amp; Management2013;18:119-26.">Fitzcharles 2013</a>), there is no other current guideline recommendation for use of any cannabis preparation in the management of fibromyalgia. </p> </section> <section id="CD011694-sec-0063"> <h5 class="title">For policy makers</h5> <p>The use of herbal cannabis at present cannot be considered evidence‐based and this should be explained to people requesting this treatment (in jurisdictions where it is allowed, e.g. Canada and Israel). </p> </section> <section id="CD011694-sec-0064"> <h5 class="title">For funders</h5> <p>Randomised controlled trials with cannabis products may be worth funding, as there are few confirmed effective drug treatments, in order to establish the efficacy and safety of cannabinoids compared to established treatments in this population. </p> </section> </section> <h3 class="title" id="CD011694-sec-0065">Implications for research</h3> <section id="CD011694-sec-0065"> <section id="CD011694-sec-0066"> <h5 class="title">Design</h5> <p>To establish whether cannabis products can have a place in the treatment of fibromyalgia would require large (at least 200 participants), randomised, double‐blind, parallel group or enriched enrolment randomised withdrawal (EERW) studies, of adequate duration (greater than 12 weeks), with outcome measures that are relevant to clinical practice (responder analysis), and analysis that does use baseline observation carried forward imputation for withdrawals. </p> <p>It might be expected that, at best, only a few people with fibromyalgia will benefit from long term use of cannabis products, and cohort studies in fibromyalgia link cannabis use to negative health‐related measures (<a href="./references#CD011694-bbs2-0071" title="Ste-MariePA , FitzcharlesMA , GamsaA , WareMA , ShirY . Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care &amp; Research (Hoboken)2012;64:1202-8.">Ste‐Marie 2012</a>). A further area of research would be to identify clinical and demographic characteristics that predict which people are likely to benefit or to be harmed from cannabis products, in order to target treatment more effectively. </p> </section> <section id="CD011694-sec-0067"> <h5 class="title">Population</h5> <p>Studies in any continent and the inclusion of people with major medical diseases and mental disorders are necessary to provide external validity of the study findings. </p> </section> <section id="CD011694-sec-0068"> <h5 class="title">Measurement (endpoints)</h5> <p>Responder criteria for pain, global impression of change and health‐related quality of life have been established (<a href="./references#CD011694-bbs2-0008" title="BennettRM , BushmakinAG , CappelleriJC , ZlatevaG , SadoskyAB . Minimal clinically important difference in the Fibromyalgia Impact Questionnaire. Journal of Rheumatology2009;36:1304-11.">Bennett 2009</a>; <a href="./references#CD011694-bbs2-0013" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]">Dworkin 2008</a>). Responder criteria for sleep problems and fatigue have not yet been developed. </p> </section> <section id="CD011694-sec-0069"> <h5 class="title">Comparison between active treatments</h5> <p>Any comparisons should be made with placebo and other drugs with known efficacy, such as pregabalin. In addition, studies comparing single therapies (e.g. cannabis products) versus combination therapies (e.g. cannabis products and aerobic exercise) are necessary. </p> </section> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011694-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011694-sec-0008"></div> <p>This review was based on a template for reviews of drugs used to relieve fibromyalgia‐associated symptoms. The aim is for all reviews to use the same methods, based on new criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD011694-bbs2-0044" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>; <a href="./appendices#CD011694-sec-0072">Appendix 1</a>). </p> <section id="CD011694-sec-0009"> <h3 class="title" id="CD011694-sec-0009">Description of the condition</h3> <p>Fibromyalgia is defined as widespread pain that lasts for longer than three months, with tenderness on palpation at 11 or more of 18 specified tender points (<a href="./references#CD011694-bbs2-0078" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33:160-72.">Wolfe 1990</a>). Chronic widespread pain is frequently associated with other symptoms such as poor sleep, fatigue and depression. People often report high disability levels and poor quality of life along with extensive use of medical care (<a href="./references#CD011694-bbs2-0082" title="WolfeF , WalittBT , HäuserW . What is fibromyalgia, how is it diagnosed and what does it really mean?Arthritis Care and Research2014;66:969-71. [DOI: 10.1002/acr.22207]">Wolfe 2014</a>). Fibromyalgia symptoms can be assessed by self report of the person using the fibromyalgia criteria and severity scales for clinical and epidemiological studies, which is a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia (<a href="./references#CD011694-bbs2-0080" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , HäuserW , KatzRS , et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Journal of Rheumatology2011;38:1113-22.">Wolfe 2011</a>). For a clinical diagnosis, the 1990 American College of Rheumatology (ACR) classification criteria (<a href="./references#CD011694-bbs2-0078" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33:160-72.">Wolfe 1990</a>) and the ACR 2010 preliminary diagnostic criteria (<a href="./references#CD011694-bbs2-0079" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research2010;62:600-10. [DOI: 10.1002/acr.20140]">Wolfe 2010</a>) can be used. Lacking a specific laboratory test, a diagnosis is established by a history of the key symptoms and the exclusion of somatic diseases that sufficiently explain these symptoms (<a href="./references#CD011694-bbs2-0079" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research2010;62:600-10. [DOI: 10.1002/acr.20140]">Wolfe 2010</a>). How fibromyalgia is considered within the international classification of diseases is under debate. While some rheumatologists have thought of it as specific pain disorder (<a href="./references#CD011694-bbs2-0011" title="ClauwD . Fibromyalgia: a clinical review. JAMA2014;311:1547-55.">Clauw 2014</a>), and central sensitivity syndrome (<a href="./references#CD011694-bbs2-0083" title="YunusMB . Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Seminars in Arthritis and Rheumatism2008;37:339-52.">Yunus 2008</a>), some neurologists conceptualise fibromyalgia as a small fibre neuropathy (<a href="./references#CD011694-bbs2-0062" title="OaklanderAL , HerzogZD , DownsHM , KleinMM . Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain2013;154:2310-6.">Oaklander 2013</a>). In psychiatry and psychosomatic medicine, fibromyalgia symptoms are characterised as a functional somatic syndrome, as a bodily distress syndrome, as a somatic symptom disorder or as a somatoform disorder (<a href="./references#CD011694-bbs2-0029" title="HäuserW , HenningsenP . Fibromyalgia syndrome - a somatoform disorder?European Journal Pain2014;18:1052-9.">Häuser 2014a</a>). </p> <p>Fibromyalgia is a heterogeneous condition. The definite aetiology (causes) of this syndrome remains unknown. A model of interacting biological and psychosocial variables in the predisposition to, triggering of, and sustaining the chronicity of fibromyalgia symptoms has been suggested (<a href="./references#CD011694-bbs2-0070" title="SommerC , HäuserW , BurgmerM , EngelhardtR , GerholdK , PetzkeF , et al. Etiology and pathophysiology of fibromyalgia syndrome [in German]. Schmerz2012;26:259-67.">Sommer 2012</a>). Depression (<a href="./references#CD011694-bbs2-0019" title="ForsethKO , HusbyG , GranJT , FørreO . Prognostic factors for the development of fibromyalgia in women with self reported musculoskeletal pain. Journal of Rheumatology1999;26:2458-67.">Forseth 1999</a>), some genes (<a href="./references#CD011694-bbs2-0005" title="ArnoldLM , FanJ , RussellIJ , YunusMB , KhanMA , KushnerI , et al. The fibromyalgia family study: a genome-wide linkage scan study. Arthritis and Rheumatism2013;65:1122-8.">Arnold 2013</a>; <a href="./references#CD011694-bbs2-0036" title="LeeYH , ChoiSJ , JiJD , SongGG . Candidate gene studies of fibromyalgia: a systematic review and meta-analysis. Rheumatology International2012;32:417-26.">Lee 2012</a>), obesity combined with physical inactivity (<a href="./references#CD011694-bbs2-0057" title="MorkPJ , VasseljenO , NilsenTI . Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trøndelag Health Study. Arthritis Care and Research2010;62:611-7.">Mork 2010</a>), physical and sexual abuse in childhood (<a href="./references#CD011694-bbs2-0026" title="HäuserW , KossevaM , ÜceylerN , KloseP , SommerC . Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis. Arthritis Care and Research2011;63:808-20.">Häuser 2011</a>), sleep problems (<a href="./references#CD011694-bbs2-0058" title="MorkPG , NilsenTI . Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis and Rheumatism2012;64:281-4.">Mork 2012</a>), and smoking (<a href="./references#CD011694-bbs2-0010" title="ChoiCJ , KnutsenR , OdaK , FraserGE , KnutsenS . The association between incident self-reported fibromyalgia and nonpsychiatric factors: 25-years follow-up of the Adventist Health Study. Journal Pain2011;11:994-1003.">Choi 2011</a>) are risk factors for the future development of fibromyalgia. Psychosocial stress (e.g. workplace and family conflicts) and physical stress (e.g. infections, surgery, accidents) might trigger the onset of chronic widespread pain and fatigue (<a href="./references#CD011694-bbs2-0011" title="ClauwD . Fibromyalgia: a clinical review. JAMA2014;311:1547-55.">Clauw 2014</a>; <a href="./references#CD011694-bbs2-0070" title="SommerC , HäuserW , BurgmerM , EngelhardtR , GerholdK , PetzkeF , et al. Etiology and pathophysiology of fibromyalgia syndrome [in German]. Schmerz2012;26:259-67.">Sommer 2012</a>). Depression and post‐traumatic stress disorder worsen fibromyalgia symptoms (<a href="./references#CD011694-bbs2-0027" title="HäuserW , GalekA , Erbslöh-MöllerB , KöllnerV , Kühn-BeckerH , LanghorstJ , et al. Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain2013;154:1216-23.">Häuser 2013a</a>; <a href="./references#CD011694-bbs2-0035" title="LangeM , PetermannF . Influence of depression on fibromyalgia: a systematic review [in German]. Schmerz2010;24:326-33.">Lange 2010</a>). </p> <p>Several physiological factors are associated with fibromyalgia, but it is unclear if they cause fibromyalgia or are the result of fibromyalgia. Alterations in pain processing in the brain, reduced reactivity of the hypothalamus‐pituitary‐adrenal axis to stress, increased pro‐inflammatory and reduced anti‐inflammatory cytokine profiles (produced by cells involved in inflammation), disturbances in neurotransmitters such as dopamine and serotonin (<a href="./references#CD011694-bbs2-0070" title="SommerC , HäuserW , BurgmerM , EngelhardtR , GerholdK , PetzkeF , et al. Etiology and pathophysiology of fibromyalgia syndrome [in German]. Schmerz2012;26:259-67.">Sommer 2012</a>), and small fibre pathology (<a href="./references#CD011694-bbs2-0062" title="OaklanderAL , HerzogZD , DownsHM , KleinMM . Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain2013;154:2310-6.">Oaklander 2013</a>; <a href="./references#CD011694-bbs2-0085" title="ÜçeylerN , ZellerD , KahnAK , KewenigS , Kittel-SchneiderS , SchmidA , et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain2013;136:e247.">Üçeyler 2013a</a>) have all been demonstrated. Prolonged exposure to stress, as outlined above, may contribute to these functional changes in predisposed individuals (<a href="./references#CD011694-bbs2-0009" title="BradleyLA . Pathophysiology of fibromyalgia. American Journal Medicine2009;122:S22-30.">Bradley 2009</a>). </p> <p>Fibromyalgia is common. Numerous studies have investigated prevalence in different settings and countries. One review gave a global mean prevalence of 2.7% (range 0.4% to 9.3%), and a mean in the Americas of 3.1%, in Europe of 2.5% and in Asia of 1.7%. It is more common in women, with a female to male ratio of 3:1 (4.2%:1.4%) (<a href="./references#CD011694-bbs2-0065" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17(8):356. [DOI: 10.1007/s11916-013-0356-5]">Queiroz 2013</a>). The change in diagnostic criteria does not appear to have significantly affected estimates of prevalence (<a href="./references#CD011694-bbs2-0081" title="WolfeF , BrählerE , HinzA , HäuserW . Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care and Research2013;645(5):777-85. [DOI: 10.1002/acr.21931]">Wolfe 2013</a>). Estimates of prevalence in specific populations vary greatly, but have been reported to be as high as 9% in female textile workers in Turkey and 10% in metalworkers in Brazil (59% in people with repetitive strain injury) (<a href="./references#CD011694-bbs2-0065" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17(8):356. [DOI: 10.1007/s11916-013-0356-5]">Queiroz 2013</a>). </p> <p>Fibromyalgia pain is known to be difficult to treat effectively, with only a minority of individuals experiencing a clinically relevant benefit from any single intervention. A multidisciplinary approach is recommended by evidence‐based guidelines, with pharmacological interventions being combined with physical or cognitive interventions, or both (<a href="./references#CD011694-bbs2-0014" title="EichW , HäuserW , ArnoldB , BernardyK , BrückleW , EidmannU , et al. Fibromyalgia syndrome: general principles and coordination of clinical care and patient education [in German]. Schmerz2012;26:268-75.">Eich 2012</a>; <a href="./references#CD011694-bbs2-0016" title="FitzcharlesMA , Ste-MariePA , GoldenbergDL , PereiraJX , AbbeyS , ChoinièreM , et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Research &amp; Management2013;18:119-26.">Fitzcharles 2013</a>). Conventional analgesics are usually not effective. Prescribed treatments typically include so‐called pain modulators such as antidepressants like serotonin and noradrenaline reuptake inhibitors (<a href="./references#CD011694-bbs2-0028" title="HäuserW , UrrútiaG , TortS , UçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD010292. [DOI: 10.1002/14651858.CD010292]">Häuser 2013b</a>; <a href="./references#CD011694-bbs2-0039" title="LunnMP , HughesRA , WiffenPJ . Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews2014, Issue 1. Art. No: CD007115. [DOI: 10.1002/14651858.CD007115.pub3]">Lunn 2014</a>), tricyclic agents such as amitriptyline (<a href="./references#CD011694-bbs2-0051" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ . Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD008242. [DOI: 10.1002/14651858.CD008242.pub2]">Moore 2012a</a>), and antiepileptics such as gabapentin or pregabalin (<a href="./references#CD011694-bbs2-0048" title="MooreRA , WiffenPJ , DerryS , McQuayHJ . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2011, Issue 3. Art. No: CD007938. [DOI: 10.1002/14651858.CD007938.pub2]">Moore 2011a</a>; <a href="./references#CD011694-bbs2-0086" title="ÜçeylerN , SommerC , WalittB , HäuserW . Anticonvulsants for fibromyalgia. Cochrane Database of Systematic Reviews2013, Issue 10. Art. No: CD010782. [DOI: 10.1002/14651858.CD010782]">Üçeyler 2013b</a>; <a href="./references#CD011694-bbs2-0077" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. Art. No: CD010567. [DOI: 10.1002/14651858.CD010567.pub2]">Wiffen 2013</a>). The proportion of people who achieve worthwhile pain relief (typically at least 50% pain intensity reduction (<a href="./references#CD011694-bbs2-0053" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12. [DOI: 10.1111/anae.12148]">Moore 2013a</a>)) is small, generally 10% to 25% more than with placebo, with numbers needed to treat for an additional beneficial outcome (NNTB) usually between 4 and 10 (<a href="./references#CD011694-bbs2-0033" title="KalsoE , AldingtonDJ , MooreRA . Drugs for neuropathic pain. BMJ2013;347:f7339. [DOI: 10.1136/bmj.f7339]">Kalso 2013</a>; <a href="./references#CD011694-bbs2-0077" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. Art. No: CD010567. [DOI: 10.1002/14651858.CD010567.pub2]">Wiffen 2013</a>). Fibromyalgia is not particularly different from other chronic pain disorders in that only a small proportion of trial participants have a good response to treatment (<a href="./references#CD011694-bbs2-0054" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690]">Moore 2013b</a>). </p> </section> <section id="CD011694-sec-0010"> <h3 class="title" id="CD011694-sec-0010">Description of the intervention</h3> <p>Current pharmacological treatment options for fibromyalgia afford only modest benefit for most people, often with adverse effects that outweigh the benefits (<a href="./references#CD011694-bbs2-0030" title="HäuserW , WalittB , FitzcharlesMA , SommerC . Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Research &amp; Therapy2014;16:201.">Häuser 2014b</a>). Therefore, there is a need to explore other treatment options, with different mechanisms of action and from different drug categories, for treatment of the constellation of symptoms that characterise fibromyalgia. The cannabinoid system is ubiquitous in the animal kingdom, with multiple functions that aid an organism in maintaining equilibrium. These stabilising effects for the organism, including modulation of pain and stress, suggest that manipulation of this system may have therapeutic potential for the management of fibromyalgia (<a href="./references#CD011694-bbs2-0064" title="PacherP , BátkaiS , KunosG . The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews2006;58:389-462.">Pacher 2006</a>). A large body of evidence currently supports the presence of cannabinoid receptors and ligands in the peripheral and central nervous system, but also in other tissues such as bone and in the immune system (<a href="./references#CD011694-bbs2-0064" title="PacherP , BátkaiS , KunosG . The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews2006;58:389-462.">Pacher 2006</a>). </p> <p>The endocannabinoid system has three broad and overlapping functions in mammals. The first is a stress recovery role, operating in a feedback loop in which endocannabinoid signalling is activated by stress and functions to return endocrine, nervous and behavioural systems to homeostatic balance. The second function is to control energy balance through regulation of the intake, storage and utilisation of food. The third involves immune regulation; endocannabinoid signalling is activated by tissue injury and modulates immune and inflammatory responses (<a href="./references#CD011694-bbs2-0024" title="HillardCJ , WeinlanderKM , StuhrKL . Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience2012;204:207-29.">Hillard 2012</a>). Thus, the endocannabinoid neuromodulatory system appears to be involved in multiple physiological functions, such as antinociception, cognition and memory, endocrine function, nausea and vomiting, inflammation and immune recognition (<a href="./references#CD011694-bbs2-0012" title="deVriesM , vanRijckevorselDC , Wilder-SmithOH , vanGoorH . Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opinion on Pharmacotherapy2014;15:1525-34.">de Vries 2014</a>; <a href="./references#CD011694-bbs2-0024" title="HillardCJ , WeinlanderKM , StuhrKL . Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience2012;204:207-29.">Hillard 2012</a>). The plant <i>Cannabis sativa</i>, commonly known as marijuana, has been used for pain relief for millennia, and has additional effects on appetite, sleep and mood (<a href="./references#CD011694-bbs2-0032" title="KalantH . Medicinal use of cannabis: history and current status. Pain Research &amp; Management2001;6:80-91.">Kalant 2001</a>). Data from clinical trials with synthetic and plant‐based cannabinoids suggest a promising approach for the management of chronic neuropathic pain of different origins (<a href="./references#CD011694-bbs2-0012" title="deVriesM , vanRijckevorselDC , Wilder-SmithOH , vanGoorH . Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opinion on Pharmacotherapy2014;15:1525-34.">de Vries 2014</a>). </p> </section> <section id="CD011694-sec-0011"> <h3 class="title" id="CD011694-sec-0011">How the intervention might work</h3> <p><i>Cannabis sativa</i> contains over 450 compounds, with at least 70 classified as phytocannabinoids. Two are of particular medical interest. Delta 9‐tetrahydrocannabinol (delta 9‐THC) is the main active constituent, with psychoactive and pain‐relieving properties. The second molecule of interest is cannabidiol, which has lesser affinity for the cannabinoid (CB) receptors and the potential to counteract the negative effects of THC on memory, mood and cognition, but also has an effect on pain modulation. The specific roles of currently identified endocannabinoids that act as ligands at cannabinoid receptors within the nervous system (primarily but not exclusively CB 1 receptors) and in the periphery (primarily but not exclusively CB 2 receptors) are only partially elucidated, but there is abundant preclinical data to support their influence on nociception (<a href="./references#CD011694-bbs2-0063" title="OwensB . Drug development: the treasure chest. Nature2015;525:S6-8.">Owens 2015</a>; <a href="./references#CD011694-bbs2-0064" title="PacherP , BátkaiS , KunosG . The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews2006;58:389-462.">Pacher 2006</a>). </p> <p>A clinical endocannabinoid deficiency has been hypothesised to underlie the pathophysiology of fibromyalgia but there is no clear evidence to support this assumption (<a href="./references#CD011694-bbs2-0067" title="RussoEB . Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?Neuro Endocrinology Letters2008;29:192-200.">Russo 2008</a>). It is also hypothesised that cannabinoids reduce sensitisation of nociceptive sensory pathways and alterations in cognitive and autonomic processing in chronic pain states (<a href="./references#CD011694-bbs2-0022" title="GuindonJ , HohmannAG . The endocannabinoid system and pain. CNS &amp; Neurological Disorders Drug Targets2009;8:403-21.">Guindon 2009</a>). The frontal‐limbic distribution of cannabinoid receptors in the brain suggests that cannabinoids may preferentially target the affective qualities of pain, believed to have an important contribution to the suffering of people with fibromyalgia (<a href="./references#CD011694-bbs2-0037" title="LeeMC , PlonerM , WiechK , BingelU , WanigasekeraV , BrooksJ , et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain2013;154:124-34.">Lee 2013</a>). In addition, cannabinoids may attenuate low‐grade inflammation, another postulate for pathogenesis in people with fibromyalgia (<a href="./references#CD011694-bbs2-0084" title="ÜçeylerN , HäuserW , SommerC . Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskeletal Disorders2011;28:245.">Üçeyler 2011</a>). Finally, some researchers believe that fibromyalgia is a stress‐related disorder (<a href="./references#CD011694-bbs2-0074" title="Van HoudenhoveB , EgleUT . Fibromyalgia: a stress disorder? Piecing the biopsychosocial puzzle together. Psychotherapy and Psychosomatics2004;73:267-75.">van Houdenhove 2004</a>). In this context, cannabinoids might function to buffer stress and modulate emotional and cognitive functions (<a href="./references#CD011694-bbs2-0024" title="HillardCJ , WeinlanderKM , StuhrKL . Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience2012;204:207-29.">Hillard 2012</a>). Therefore, taking into consideration the complexity of symptom expression and the absence of an ideal treatment, the potential for manipulation of the cannabinoid system as a therapeutic modality is attractive. </p> </section> <section id="CD011694-sec-0012"> <h3 class="title" id="CD011694-sec-0012">Why it is important to do this review</h3> <p>Cannabinoids may be administered therapeutically as a pharmaceutic product that is either synthetic or derived from the plant base, or by use of the herbal product that is not pharmaceutically manufactured. The therapeutic use of synthetic and plant‐based cannabinoids has been widely reviewed (<a href="./references#CD011694-bbs2-0012" title="deVriesM , vanRijckevorselDC , Wilder-SmithOH , vanGoorH . Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opinion on Pharmacotherapy2014;15:1525-34.">de Vries 2014</a>; <a href="./references#CD011694-bbs2-0022" title="GuindonJ , HohmannAG . The endocannabinoid system and pain. CNS &amp; Neurological Disorders Drug Targets2009;8:403-21.">Guindon 2009</a>; <a href="./references#CD011694-bbs2-0064" title="PacherP , BátkaiS , KunosG . The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews2006;58:389-462.">Pacher 2006</a>), but clinical use so far has been conflicting. Several practical problems, as well as ethical issues, arise in view of the illegality of the plant <i>Cannabis sativa</i> in many jurisdictions, the prevalent worldwide use of <i>Cannabis sativa</i> as a recreational drug and the potential for the abuse of cannabinoid preparations (<a href="./references#CD011694-bbs2-0012" title="deVriesM , vanRijckevorselDC , Wilder-SmithOH , vanGoorH . Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opinion on Pharmacotherapy2014;15:1525-34.">de Vries 2014</a>). However, various cannabinoid preparations are legally available for some medical treatment in some parts of the world (e.g. US, Canada, Europe, Africa) and herbal cannabis has been recently legalised for therapeutic use in over 20 states in the US and also in Canada and Israel. The use of synthetic cannabis has been tested in uncontrolled trials in fibromyalgia (<a href="./references#CD011694-bbs2-0069" title="SchleyM , LeglerA , SkoppG , SchmelzM , KonradC , RukwiedR . Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Current Medical Research and Opinion2006;27:1269-76.">Schley 2006</a>; <a href="./references#CD011694-bbs2-0076" title="WeberJ , SchleyM , CasuttM , GerberH , SchuepferG , RukwiedR , et al. Tetrahydrocannabinol (Delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: results of a multicenter survey. Anesthesiology Research and Practice2009;2009:pii: 827290.">Weber 2009</a>), and has been advocated by some pain specialists (<a href="./references#CD011694-bbs2-0076" title="WeberJ , SchleyM , CasuttM , GerberH , SchuepferG , RukwiedR , et al. Tetrahydrocannabinol (Delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: results of a multicenter survey. Anesthesiology Research and Practice2009;2009:pii: 827290.">Weber 2009</a>). Therefore, physicians will be caring for people who may be self medicating with herbal cannabis or may request medical advice about cannabis (<a href="./references#CD011694-bbs2-0017" title="FitzcharlesMA , ClauwDJ , Ste-MariePA , ShirY . The dilemma of medical marijuana use by rheumatology patients. Arthritis Care and Research2014;66:797-801.">Fitzcharles 2014</a>). Due to this, we see an immediate need to evaluate the efficacy, tolerability and safety of cannabinoids in fibromyalgia in order to assist people with fibromyalgia and doctors in shared decision‐making on additional pharmacological treatment options. </p> <p>The standards used to assess evidence in chronic pain trials have changed substantially, with particular attention being paid to trial duration, withdrawals and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy. The most important change is the move from using mean pain scores, or mean change in pain scores, to the number of participants who have a large decrease in pain (by at least 50%) and who continue in treatment, ideally in trials of eight to 12 weeks or longer. Pain intensity reduction of 50% or more correlates with improvements in co‐morbid symptoms, function and quality of life. These standards are set out in the reference guide for pain studies (<a href="./references#CD011694-bbs2-0006" title="PaPaS author and referee guidance. papas.cochrane.org/papas-documents (accessed 22 January 2015).">AUREF 2012</a>). </p> <p>This Cochrane review will assess evidence in ways that make both statistical and clinical sense, and will use developing criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD011694-bbs2-0044" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>). Trials included and analysed will need to meet a minimum of reporting quality (blinding, randomisation), validity (duration, dose and timing, diagnosis, outcomes, etc.), and size (ideally at least 500 participants in a comparison in which the NNTB is four or above (<a href="./references#CD011694-bbs2-0042" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]">Moore 1998</a>)). This sets high standards and marks a departure from how reviews were done previously. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011694-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011694-sec-0013"></div> <p>To assess the efficacy, tolerability and safety of cannabinoids for fibromyalgia symptoms in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011694-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011694-sec-0014"></div> <section id="CD011694-sec-0015"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011694-sec-0016"> <h4 class="title">Types of studies</h4> <p>We included studies if they were randomised, double‐blind controlled trials (RCTs) of at least four weeks' duration. We included studies with a parallel, cross‐over and enriched enrolment randomised withdrawal (EERW) design. Trials had at least 10 participants per treatment arm. We required full journal publication, with the exception of online clinical trial result summaries of otherwise unpublished clinical trials, and abstracts with sufficient data for analysis. We did not include short abstracts. We excluded studies that were non‐randomised, studies of experimental pain, case reports and clinical observations. </p> </section> <section id="CD011694-sec-0017"> <h4 class="title">Types of participants</h4> <p>We included studies with adults aged 18 years and above, diagnosed with fibromyalgia using the 1990 or 2010 criteria (<a href="./references#CD011694-bbs2-0078" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33:160-72.">Wolfe 1990</a>; <a href="./references#CD011694-bbs2-0079" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research2010;62:600-10. [DOI: 10.1002/acr.20140]">Wolfe 2010</a>). </p> </section> <section id="CD011694-sec-0018"> <h4 class="title">Types of interventions</h4> <p>Cannabinoids (either phytocannabinoids such as herbal cannabis (hashish, marihuana), plant‐based cannabinoids (nabiximole) or pharmacological (synthetic) cannabinoids (e.g. cannabidiol, dronabinol, levonantradol, nabilone)), at any dose, by any route, administered for the relief of fibromyalgia symptoms and compared to placebo or any active comparator. We did not include studies with drugs under development that manipulated the endocannabinoid system by inhibiting enzymes that hydrolysed endocannabinoids and thereby boosted the levels of the endogenous molecules (e.g. blockade of the catabolic enzyme fatty acid amide hydrolase (FAAH)) (<a href="./references#CD011694-bbs2-0038" title="LongJZ , NomuraDK , VannRE , WalentinyDM , BookerL , JinX , et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proceedings of the National Academy of Science of the United States of America2009;106:20270-5.">Long 2009</a>). </p> </section> <section id="CD011694-sec-0019"> <h4 class="title">Types of outcome measures</h4> <p>We anticipated that studies would use a variety of outcome measures, with the majority of studies using standard subjective scales (numerical rating scale (NRS) or visual analogue scale (VAS) for pain intensity or pain relief, or both. We were particularly interested in Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (<a href="./references#CD011694-bbs2-0013" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]">Dworkin 2008</a>). These were defined as at least 30% pain relief over baseline (moderate), at least 50% pain relief over baseline (substantial), much or very much improved on Patient Global Impression of Change (PGIC) (moderate) and very much improved on PGIC (substantial). These outcomes are different from those used in most earlier reviews, concentrating as they do on dichotomous outcomes where pain responses do not follow a normal (Gaussian) distribution. People with chronic pain desire high levels of pain relief, ideally more than 50%, and with pain not worse than mild (<a href="./references#CD011694-bbs2-0053" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12. [DOI: 10.1111/anae.12148]">Moore 2013a</a>; <a href="./references#CD011694-bbs2-0061" title="O'BrienEM , StaudRM , HassingerAD , McCullochRC , CraggsJG , AtchisonJW , et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine2010;11(1):6-15. [DOI: 10.1111/j.1526-4637.2009.00685.x]">O'Brien 2010</a>). </p> <p>We planned to include a 'Summary of findings' table as set out in the author guide (<a href="./references#CD011694-bbs2-0006" title="PaPaS author and referee guidance. papas.cochrane.org/papas-documents (accessed 22 January 2015).">AUREF 2012</a>). The 'Summary of findings' table was planned to include outcomes of at least 50% pain reduction, PGIC, adverse event withdrawals, serious adverse events and death. </p> <section id="CD011694-sec-0020"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011694-list-0001"> <li> <p>Participant‐reported pain relief of 50% or greater.</p> </li> <li> <p>PGIC much or very much improved.</p> </li> <li> <p>Withdrawal due to adverse events (tolerability).</p> </li> <li> <p>Serious adverse events (safety). Serious adverse events typically include any untoward medical occurrence or effect that at any dose results in death, is life‐threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an 'important medical event' that may jeopardise the person, or may require an intervention to prevent one of the above characteristics/consequences. </p> </li> </ol> </p> </section> <section id="CD011694-sec-0021"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011694-list-0002"> <li> <p>Participant‐reported pain relief of 30% or greater.</p> </li> <li> <p>Sleep problems.</p> </li> <li> <p>Fatigue.</p> </li> <li> <p>Depression.</p> </li> <li> <p>Anxiety.</p> </li> <li> <p>Health‐related quality of life (HRQoL).</p> </li> <li> <p>Disability.</p> </li> <li> <p>Withdrawals due to lack of efficacy.</p> </li> <li> <p>Participants experiencing any adverse event.</p> </li> <li> <p>Other specific adverse events, particularly somnolence, dizziness and drug prescription abuse (addiction). </p> </li> </ol> </p> </section> </section> </section> <section id="CD011694-sec-0022"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011694-sec-0023"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases, without language restrictions:</p> <p> <ol id="CD011694-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3 of 12, 2016);</p> </li> <li> <p>MEDLINE (via Ovid) (to 26 April 2016);</p> </li> <li> <p>EMBASE (via Ovid) (to 26 April 2016).</p> </li> </ol> </p> <p>See <a href="./appendices#CD011694-sec-0073">Appendix 2</a> for the CENTRAL search strategy, <a href="./appendices#CD011694-sec-0074">Appendix 3</a> for the MEDLINE search strategy and <a href="./appendices#CD011694-sec-0075">Appendix 4</a> for the EMBASE search strategy. </p> </section> <section id="CD011694-sec-0024"> <h4 class="title">Searching other resources</h4> <p>We reviewed the bibliographies of any randomised trials identified and review articles, contacted the authors and known experts in the field, and searched clinical trial databases (ClinicalTrials.gov (<a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>), International Association for Cannabinoid Medicines (IACM) databank (<a href="http://www.cannabis-med.org/studies/study.php" target="_blank">www.cannabis-med.org/studies/study.php</a>), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) to identify additional published or unpublished data and ongoing trials. </p> </section> </section> <section id="CD011694-sec-0025"> <h3 class="title" id="CD011694-sec-0025">Data collection and analysis</h3> <section id="CD011694-sec-0026"> <h4 class="title">Selection of studies</h4> <p>Two review authors (WH, BW) determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy the inclusion criteria, and obtained full copies of the remaining studies. Two review authors (MAF, WH) independently read these studies and reached agreement by discussion. We did not anonymise the studies before assessment. We created a PRISMA flow chart of the screening process (see <a href="#CD011694-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011694-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011694-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/image_n/nCD011694-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011694-sec-0027"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MAF, WH) independently extracted data using a standard form and checked for agreement. One review author (WH) entered suitable data Review Manager 5 (<a href="./references#CD011694-bbs2-0066" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We included information about the pain condition and number of participants treated, drug and dosing regimen, study design (placebo or active control), inclusion and exclusion criteria, study setting, study duration and follow‐up, outcome measures and results, withdrawals and adverse events (participants experiencing any adverse event or serious adverse event). </p> </section> <section id="CD011694-sec-0028"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Oxford Quality Score as the basis for inclusion (<a href="./references#CD011694-bbs2-0031" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Controlled Clinical Trials1996;17(1):1-12. [DOI: doi.org/10.1016/0197-2456(95)00134-4]">Jadad 1996</a>), limiting inclusion to studies that were randomised and double‐blind as a minimum. </p> <p>Two review authors (WH, MAF) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011694-bbs2-0023" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>), and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We assessed the following for each study. </p> <p> <ol id="CD011694-list-0004"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies at high risk of bias that used a non‐random process (e.g. odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation and were therefore at a high risk of bias (e.g. open list). </p> </li> <li> <p>Blinding of participants and personnel/treatment providers (systematic performance bias). We assessed the methods used to blind participants and personnel/treatment providers from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, e.g. identical tablets; matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved); high risk of bias (blinding of participants was not ensured, e.g. tablets different in form or taste). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, e.g. identical tablets, matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We excluded studies at a high risk of bias that were not double‐blind. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk of bias (i.e. less than 10% of participants did not complete the study or used 'baseline observation carried forward' analysis, or both); unclear risk of bias (used last observation carried forward (LOCF) analysis); or high risk of bias (used completer analysis). </p> </li> <li> <p>Reporting bias due to selective outcome reporting (reporting bias). We checked if an a priori study protocol was available and if all outcomes of the study protocol were reported in the publications of the study. There was low risk of reporting bias if the study protocol was available and all of the study's pre‐specified (primary and secondary) outcomes that were of interest in the review were reported in the pre‐specified way, or if the study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon). There was a high risk of reporting bias if not all of the study's pre‐specified primary outcomes were reported; one or more primary outcomes was reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified; one or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting was provided, such as an unexpected adverse effect); one or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta‐analysis; the study report did not include results for a key outcome that would be expected to have been reported for such a study. </p> </li> <li> <p>Group similarity at baseline (selection bias). We assessed similarity of the study groups at baseline for the most important prognostic clinical and demographic indicators. There was low risk of bias if groups were similar at baseline for demographic factors, value of main outcome measure(s) and important prognostic factors. There was unclear risk of bias if important prognostic clinical and demographic indicators were not reported. There was high risk of bias if groups were not similar at baseline for demographic factors, value of main outcome measure(s), and important prognostic factor. </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies at low risk of bias (i.e. 200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); or high risk of bias (fewer than 50 participants per treatment arm). </p> </li> </ol> </p> <p>Two review authors (WH, MFA) made quality ratings separately for each of the seven methodology quality indicators as defined by the 'Risk of bias' tool. We defined a study to be of high quality when it fulfilled six to eight of the indicators (no risk of bias), to be of moderate quality when it fulfilled three to five of the indicators and to be of low quality if it fulfilled zero to two of the quality indicators (<a href="./references#CD011694-bbs2-0068" title="SchaefertR , WelschP , KloseP , SommerC , PetzkeF , HäuserW . Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration [in German]. Schmerz2015;29:47-59.">Schaefert 2015</a>). </p> </section> <section id="CD011694-sec-0029"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to calculate numbers needed to treat as the reciprocal of the absolute risk reduction (ARR) (<a href="./references#CD011694-bbs2-0041" title="McQuayH , MooreR . An Evidence-based Resource for Pain Relief. Oxford: Oxford University Press, 1998.">McQuay 1998</a>). For unwanted effects, the number needed to treat for an additional beneficial outcome (NNTB) became the number needed to treat for an additional harm outcome (NNTH) and was calculated in the same manner. We planned to use dichotomous data to calculate risk ratio (RR) with 95% confidence intervals (CI) using a fixed‐effect model unless we found significant statistical or clinical heterogeneity (see below). We planned to calculate standardised mean differences (SMD) with 95% CI for continuous variables using a fixed‐effect model unless we found significant statistical or clinical heterogeneity. We planned to calculate NNTBs for continuous variables (fatigue, sleep problems, HRQoL) using the Wells calculator software available at the Cochrane Musculoskeletal Group editorial office, which estimates, from the SMDs, the proportion of participants who will benefit from treatment (<a href="./references#CD011694-bbs2-0060" title="NormanGR , SridharFG , GuyattGH , WalterSD . Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Medical Care2001;39:1039-47.">Norman 2001</a>). We planned to use a minimal clinically important difference of 15% for the calculation of the NNTB from SMDs for all continuous outcomes. This approach has been used by previous Cochrane reviews in drug therapies for fibromyalgia (<a href="./references#CD011694-bbs2-0028" title="HäuserW , UrrútiaG , TortS , UçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD010292. [DOI: 10.1002/14651858.CD010292]">Häuser 2013b</a>; <a href="./references#CD011694-bbs2-0086" title="ÜçeylerN , SommerC , WalittB , HäuserW . Anticonvulsants for fibromyalgia. Cochrane Database of Systematic Reviews2013, Issue 10. Art. No: CD010782. [DOI: 10.1002/14651858.CD010782]">Üçeyler 2013b</a>). </p> <p>Where means or standard deviations (SDs) were missing, we attempted to obtain these data through contacting trial authors. Where SDs were not available from trial authors, we calculated them from t values, P values, CIs or standard errors, where reported in articles (<a href="./references#CD011694-bbs2-0023" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Where 30% and 50% pain reduction rates were not reported or provided on request, we planned to calculate them from means and SDs using a validated imputation method (<a href="./references#CD011694-bbs2-0020" title="FurukawaTA , CiprianiA , BarbuiC , BrambillaP , WatanabeN . Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology2005;29:49-52.">Furukawa 2005</a>). </p> </section> <section id="CD011694-sec-0030"> <h4 class="title">Unit of analysis issues</h4> <p>We intended to split the control treatment arm between active treatment arms in a single study if the active treatment arms were not combined for analysis. We included studies with a cross‐over design where separate data from the two periods were reported, where data were presented that excluded a statistically significant carry‐over effect, or where statistical adjustments were carried out in case of a significant carry‐over effect. </p> </section> <section id="CD011694-sec-0031"> <h4 class="title">Dealing with missing data</h4> <p>We planned to use an intention‐to‐treat (ITT) analysis where the ITT population consisted of participants who were randomised, took at least one dose of the assigned study medication and provided at least one post‐baseline assessment. We would have assigned missing participants zero improvement wherever possible. </p> </section> <section id="CD011694-sec-0032"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by analysing the inclusion and exclusion criteria of the studies included. We assessed statistical heterogeneity visually (<a href="./references#CD011694-bbs2-0034" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta-analysis in clinical research. Annals of Internal Medicine1987;107:224-33.">L'Abbé 1987</a>), and with the use of the I<sup>2</sup> statistic. When the I<sup>2</sup> value was greater than 50%, we would have considered possible reasons for this. </p> </section> <section id="CD011694-sec-0033"> <h4 class="title">Assessment of reporting biases</h4> <p>We aimed to use dichotomous outcomes of known utility and of value to participants as primary outcomes (<a href="./references#CD011694-bbs2-0045" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039]">Moore 2010b</a>; <a href="./references#CD011694-bbs2-0053" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12. [DOI: 10.1111/anae.12148]">Moore 2013a</a>). We extracted and used continuous data, which probably reflect efficacy and utility poorly, for illustrative purposes only. </p> </section> <section id="CD011694-sec-0034"> <h4 class="title">Data synthesis</h4> <p>We planned to analyse data in three tiers, according to outcome and freedom from known sources of bias (<a href="./references#CD011694-bbs2-0044" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>). </p> <p> <ol id="CD011694-list-0005"> <li> <p>The first tier used data meeting current best standards, where studies reported the outcome of at least 50% pain intensity reduction over baseline (or its equivalent), without the use of LOCF or other imputation method for drop‐outs, reported an ITT analysis, lasted eight or more weeks, had a parallel‐group design and had at least 200 participants (preferably at least 400) in the comparison (<a href="./references#CD011694-bbs2-0042" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]">Moore 1998</a>; <a href="./references#CD011694-bbs2-0044" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>; <a href="./references#CD011694-bbs2-0051" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ . Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD008242. [DOI: 10.1002/14651858.CD008242.pub2]">Moore 2012a</a>; <a href="./references#CD011694-bbs2-0052" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]">Moore 2012b</a>). We planned to report these first‐tier results first. </p> </li> <li> <p>The second tier used data from at least 200 participants but where one or more of the first‐tier conditions were not met (e.g. reporting at least 30% pain intensity reduction, using LOCF or a completer analysis, or lasting four to eight weeks). </p> </li> <li> <p>The third tier of evidence related to data from fewer than 200 participants, or where there were significant problems because, for example, of very short duration studies of fewer than four weeks, where there was major heterogeneity between studies, or where there were shortcomings in allocation concealment, attrition or incomplete outcome data. For this third tier of evidence, no data synthesis was reasonable and may be misleading, but an indication of beneficial effects might be possible. </p> </li> </ol> </p> <p>There was only third‐tier evidence available. For this third‐tier evidence, no data synthesis was reasonable and may have been misleading. Therefore, we did not conduct the planned meta‐analysis. </p> <p>We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the overall quality of evidence (<a href="./references#CD011694-bbs2-0007" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64:401-6.">Balshem 2011</a>; <a href="./references#CD011694-bbs2-0021" title="McMaster UniversityGRADEpro GDT 2015: GRADEpro Guideline Development Tool. McMaster University, 2015.">GRADEpro GDT 2015</a>), defined as the extent of confidence in the estimates of treatment benefits and harms. We downgraded the quality of evidence by one level for each of the following factors that we encountered. </p> <p> <ol id="CD011694-list-0006"> <li> <p>Limitations of study design: greater than 50% of the participants in low quality studies.</p> </li> <li> <p>Inconsistency of effect size: I<sup>2</sup> greater than 50%. </p> </li> <li> <p>Indirectness: we assessed whether the question being addressed in this systematic review was different from the available evidence regarding the population in routine clinical care, if people with inflammatory rheumatic diseases or depressive disorders (or both) were excluded in greater than 50% of participants. </p> </li> <li> <p>Imprecision: there was only one trial or when there was more than one trial, the total number was fewer than 400 participants or when 95% CI of the effect size included zero. </p> </li> <li> <p>High probability of reporting bias: all studies were sponsored by the manufacturer of the drug. </p> </li> </ol> </p> <p>We categorised the quality of evidence as follows.</p> <p> <ol id="CD011694-list-0007"> <li> <p>High: we were very confident that the true effect lay close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we were moderately confident in the effect estimate; the true effect was likely to be close to the estimate of the effect, but there was a possibility that it was substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate was limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we had very little confidence in the effect estimate; the true effect was likely to be substantially different from the estimate of effect; any estimate of effect was very uncertain. </p> </li> </ol> </p> <p>We planned to present the main findings of the review in 'Summary of findings' tables in a transparent and simple tabular format. Due to the scarcity of data, we were unable to create a GRADE 'Summary of findings' table. </p> </section> <section id="CD011694-sec-0035"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses (studies with and without stratification for co‐morbid mental disorders; different cannabinoids; different routes of administration) if there were at least two studies available. </p> <p>The planned subgroup analyses were not possible due to the lack of a sufficient number of studies. </p> </section> <section id="CD011694-sec-0036"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform sensitivity analysis because we did not identify individual peculiarities of the studies under investigation during the review process that were suitable for sensitivity analyses. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011694-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011694-sec-0037"></div> <section id="CD011694-sec-0038"> <h3 class="title">Description of studies</h3> <section id="CD011694-sec-0039"> <h4 class="title">Results of the search</h4> <p>Searches identified three potentially relevant studies in CENTRAL, 20 in MEDLINE and 47 in EMBASE. In addition, we identified two study protocols in <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>. After reading the full reports, we included two studies into the review (<a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a>; <a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a>). We excluded two studies (<a href="./references#CD011694-bbs2-0003" title="NCT00176163. Supporting effect of dronabinol on behavioral therapy in fibromyalgia and chronic back pain. clinicaltrials.gov/ct2/show/NCT00176163 (accessed 27 June 2016). ">NCT00176163</a>; <a href="./references#CD011694-bbs2-0004" title="NCT01149018. Efficacy trial of oral tetrahydrocannabinol in patients with fibromyalgia. clinicaltrials.gov/ct2/show/NCT01149018 (accessed 27 June 2016). ">NCT01149018</a>) (see <a href="#CD011694-fig-0001">Figure 1</a>). </p> </section> <section id="CD011694-sec-0040"> <h4 class="title">Included studies</h4> <p>We included two studies with 72 participants using nabilone in people with fibromyalgia (<a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a>; <a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a>). Study recruitment was from a chronic pain specialist clinic (<a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a>), and from a Musculoskeletal Rehabilitation clinic (<a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a>) (single centre studies). Both studies were conducted in Canada. Studies enrolled adults with aged between 26 and 76 years, with no upper age limits in one study (<a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a>), and upper limit of 75 years in the other study (<a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a>). In both studies, there was a preponderance of women (ca 90%). Inclusion criterion was continued pain despite the use of other oral medications (<a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a>), or self reported chronic insomnia (<a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a>) (see <a href="./appendices#CD011694-sec-0076">Appendix 5</a>). Diagnosis of fibromyalgia was established by the ACR 1990 classification criteria in both studies (<a href="./references#CD011694-bbs2-0078" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33:160-72.">Wolfe 1990</a>). Exclusion criteria in both studies included a history of substance abuse, current psychotic disorders and unstable cardiac disease. The extent of other exclusion criteria varied between studies. One study with the majority of participants in the review excluded people with "History of untreated non‐psychotic emotional disorders" (<a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a>) (see <a href="./appendices#CD011694-sec-0076">Appendix 5</a>). Nabilone was compared with placebo (<a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a>) and with amitriptyline (<a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a>). One study used a parallel group design (<a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a>); the other was a cross‐over study (<a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a>). Study duration was four weeks (<a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a>) and six weeks (two weeks each for each period, separated by a two weeks' wash‐out phase) (<a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a>). <a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a> reported data from the first phase separately only for the main outcome sleep problems. To assess potential carryover effects, examination of treatment by period interactions was conducted. Other stable medication (including pain medication) was continued unchanged in both studies. There was a two‐week washout between phases in the cross‐over study (<a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a>). The dosage of nabilone was progressively increased from 0.5 mg/day to 1 mg/day at bedtime in both studies. </p> <p>See <a href="./references#CD011694-sec-0090" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD011694-sec-0041"> <h4 class="title">Excluded studies</h4> <p>We excluded two studies after reading the full reports (<a href="./references#CD011694-bbs2-0003" title="NCT00176163. Supporting effect of dronabinol on behavioral therapy in fibromyalgia and chronic back pain. clinicaltrials.gov/ct2/show/NCT00176163 (accessed 27 June 2016). ">NCT00176163</a>; <a href="./references#CD011694-bbs2-0004" title="NCT01149018. Efficacy trial of oral tetrahydrocannabinol in patients with fibromyalgia. clinicaltrials.gov/ct2/show/NCT01149018 (accessed 27 June 2016). ">NCT01149018</a>). Reasons for exclusion of individual studies are listed in the <a href="./references#CD011694-sec-0091" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD011694-sec-0042"> <h3 class="title">Risk of bias in included studies</h3> <p>Each study had at least two high risks of bias (<a href="#CD011694-sec-0028">Assessment of risk of bias in included studies</a>). See <a href="#CD011694-fig-0002">Figure 2</a>; <a href="#CD011694-fig-0003">Figure 3</a>. The reported methodology quality of the trials was moderate according to the pre‐defined criteria. </p> <div class="figure" id="CD011694-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011694-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/image_n/nCD011694-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011694-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011694-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/image_n/nCD011694-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011694-sec-0043"> <h4 class="title">Allocation</h4> <p>Both studies were randomised. Random sequence generation and allocation concealment were of low risk in <a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a>. In <a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a>, the details of randomisation were unclear. </p> </section> <section id="CD011694-sec-0044"> <h4 class="title">Blinding</h4> <p>Both studies were double blind. Both studies adequately described the method used to achieve double blinding. </p> </section> <section id="CD011694-sec-0045"> <h4 class="title">Incomplete outcome data</h4> <p>Both studies did not perform ITT, but completer analysis.</p> </section> <section id="CD011694-sec-0046"> <h4 class="title">Selective reporting</h4> <p>A study protocol was not available for either study.</p> </section> <section id="CD011694-sec-0047"> <h4 class="title">Other potential sources of bias</h4> <p>The demographic characteristics of the study groups were not different in both studies. The sample size of both studies were small. Both studies were partially funded by the manufacturer of nabilone. </p> </section> </section> <section id="CD011694-sec-0048"> <h3 class="title" id="CD011694-sec-0048">Effects of interventions</h3> <p>Both included studies reported at least one pain‐related outcome. Due to the scarcity of data, we did not create a 'Summary of findings' table. See <a href="./appendices#CD011694-sec-0077">Appendix 6</a> and <a href="./appendices#CD011694-sec-0078">Appendix 7</a> for details of data from individual studies. There was no first‐ or second‐tier (high to moderate quality) evidence of efficacy, tolerability and safety. The studies did not report outcomes for proportion of participants experiencing at least 30% or 50% pain relief or who were very much improved. The quality of evidence for all outcomes was downgraded by three levels because of indirectness, imprecision and potential reporting bias to very low. </p> <section id="CD011694-sec-0049"> <h4 class="title">Third‐tier evidence</h4> <section id="CD011694-sec-0050"> <h5 class="title">Efficacy</h5> <p>The quality of evidence for all outcomes of efficacy was very low.</p> <p>Using a responder analysis, <a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a> reported that statistically significant improvements were detected in pain, anxiety and HRQoL. However, calculating SMDs by the means and SDs extracted from figures, we did not find a significant difference between nabilone and placebo. There were no significant differences between nabilone and placebo noted for fatigue and depression. The outcome disability was not reported. No participant dropped out due to lack of efficacy in the nabilone or placebo group. </p> <p>Nabilone had better effects on sleep than amitriptyline (adjusted difference ‐3.25, 95% CI ‐5.26 to ‐1.24; P value &lt; 0.05) on a 0 to 28 scale (Insomnia severity index). There were no significant differences between the two drugs for pain and HRQoL. There were no data for the Fibromyalgia Impact Questionnaire (FIQ) subscales anxiety, disability, fatigue and depression. There were no significant differences between the two drugs in the Profile of Mood States. One participant dropped out due to the lack of efficacy. The authors did not report if the drop‐out due to the lack of efficacy was in the nabilone or amitriptyline group. All results were based on a responder analysis (<a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a>). </p> <p>Neither study assessed the outcomes participant‐reported pain relief of 30% or 50% or greater, or PGIC much or very much improved. The data provided by both studies did not allow the use of the planned imputation method to calculate 30% and 50% pain responder rates (<a href="./references#CD011694-bbs2-0020" title="FurukawaTA , CiprianiA , BarbuiC , BrambillaP , WatanabeN . Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology2005;29:49-52.">Furukawa 2005</a>). </p> </section> <section id="CD011694-sec-0051"> <h5 class="title">Tolerability</h5> <p>The quality of evidence for all outcomes of tolerability was very low.</p> <p>Both studies did not report the numbers of participants who experienced any adverse event. <a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a> did not report the total number of adverse events. <a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a> reported 187 adverse events. Fifty‐three adverse events were possibly or probably related to amitriptyline therapy and 91 AEs to nabilone therapy. </p> <p>Three out of 20 participants in the nabilone group and 1/20 participant in the placebo group dropped out due to adverse events in the <a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a> study. <a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a> reported that 1/32 participant dropped out in the nabilone group and no participants in the amitriptyline group dropped out due to adverse events. The most frequent adverse events were drowsiness (seven participants with nabilone, one participant with placebo), dry mouth (five participants with nabilone, one participant with placebo) and vertigo (four participants with nabilone, no participants with placebo) in <a href="./references#CD011694-bbs2-0001" title="SkrabekRQ , GalimovaL , EthansK , PerryD . Nabilone for the treatment of pain in fibromyalgia. Journal of Pain2008;9:164-73. ">Skrabek 2008</a>. The most frequent adverse events were dizziness (10 participants with nabilone, four participants with amitriptyline), nausea (nine participants with nabilone, one participant with amitriptyline), dry mouth (seven participants with nabilone, three participants with amitriptyline) and drowsiness (six participants with nabilone, one participant with amitriptyline) in <a href="./references#CD011694-bbs2-0002" title="WareMA , FitzcharlesMA , JosephL , ShirY . The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia &amp; Analgesia2010;110:604-10. ">Ware 2010</a>. Neither study reported on abuse of prescribed nabilone. </p> </section> <section id="CD011694-sec-0052"> <h5 class="title">Safety</h5> <p>The quality of evidence for all outcomes of safety was very low. Both studies reported no serious adverse events during the study period. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011694-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011694-sec-0053"></div> <section id="CD011694-sec-0054"> <h3 class="title" id="CD011694-sec-0054">Summary of main results</h3> <p>The review found two studies testing the synthetic cannabinoid nabilone in 72 participants with FM. No first‐ or second‐tier evidence was available. </p> <p>There was no unbiased evidence of a superiority of nabilone over placebo to reduce fibromyalgia symptoms. Third‐tier evidence indicated a superiority of nabilone over placebo in pain relief and HRQoL, but not in fatigue, but this was derived from group mean data and completer analysis in a small, short duration study, where major bias was possible. Third‐tier evidence indicated a superiority of nabilone over amitriptyline in improving sleep quality, but not for pain and HRQoL, but this was derived from group mean data and completer analysis in a small, short duration study, where major bias is possible. Participants taking nabilone experienced more adverse events (but not serious adverse events) than did participants taking placebo or amitriptyline. More participants dropped out due to adverse events in the nabilone than in the control groups. The most frequent adverse events with nabilone were dizziness/drowsiness, dry mouth and vertigo. We found no RCTs with other cannabinoids than nabilone. </p> </section> <section id="CD011694-sec-0055"> <h3 class="title" id="CD011694-sec-0055">Overall completeness and applicability of evidence</h3> <p>Overall completeness and applicability of evidence were poor. The usefulness of the available evidence was limited because reporting quality was poor by current standards (<a href="./references#CD011694-bbs2-0044" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>). RCTs of up to six weeks' duration do not necessarily provide information about longer term use, which is important in treatment of a chronic condition (<a href="./references#CD011694-bbs2-0044" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>). In particular, concern has been raised about the lack of evidence on potential problems with long term recreational use of cannabis (such as safety issues, addiction and misuse) (<a href="./references#CD011694-bbs2-0025" title="HochE , BonnetU , ThomasisusR , GanzerF , Havemann-ReineckeU , PreussUW . Risks associated with the non-medical use of cannabis. Deutsches Arzteblatt International2015;112:271-8.">Hoch 2015</a>; <a href="./references#CD011694-bbs2-0075" title="VolkowND , ComptonWM , WeissSR . Adverse health effects of marijuana use. New England Journal of Medicine2014;371:879.">Volkow 2014</a>). A very limited population was studied, who may not be representative for people with fibromyalgia in routine clinical care. </p> </section> <section id="CD011694-sec-0056"> <h3 class="title" id="CD011694-sec-0056">Quality of the evidence</h3> <p>While both the included studies were randomised and double‐blind, neither provided data that met pre‐defined criteria for first‐ or second‐tier analysis (high to moderate quality evidence). Both studies were small (the largest treatment group consisted of 40 participants). The studies were of short duration (maximum treatment period of four weeks) and one was of cross‐over design without separate reporting of first period data. Both studies used completer analysis. The quality of evidence according to GRADE for all outcomes of efficacy, tolerability and safety was very low, downgraded for the reasons given in <a href="#CD011694-sec-0042">Risk of bias in included studies</a>. </p> </section> <section id="CD011694-sec-0057"> <h3 class="title" id="CD011694-sec-0057">Potential biases in the review process</h3> <p>The absence of publication bias (unpublished trials showing no benefit of cannabinoids over placebo) can never be proved. We carried out a broad search of studies and felt it was unlikely that significant amounts of relevant data remain unknown to us. The degree of exaggeration of treatment effects in cross‐over trials compared to parallel group designs is a potential source of major bias (<a href="./references#CD011694-bbs2-0015" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving crossover trials: methodological issues. International Journal of Epidemiology2002;31:140-9.">Elbourne 2002</a>). </p> </section> <section id="CD011694-sec-0058"> <h3 class="title" id="CD011694-sec-0058">Agreements and disagreements with other studies or reviews</h3> <p>The evidence for efficacy of cannabinoids for fibromyalgia symptoms in uncontrolled trials and surveys is as inconsistent as the RCTs reviewed. In one experimental study designed to examine the effect of orally administered delta 9‐THC on electrically induced pain, nine people with fibromyalgia from Germany received a daily dose of 2.5 to 15 mg of delta 9‐THC, with a weekly increase of 2.5 mg, as long as no adverse events were reported. Five participants withdrew due to adverse events. Daily recorded pain of the people with fibromyalgia was significantly reduced over a three‐month period (<a href="./references#CD011694-bbs2-0069" title="SchleyM , LeglerA , SkoppG , SchmelzM , KonradC , RukwiedR . Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Current Medical Research and Opinion2006;27:1269-76.">Schley 2006</a>). One case series of 172 participants reported from Germany included 32 people with fibromyalgia. On average, participants received delta 9‐THC 7.5 mg over seven months. Participants were assessed retrospectively in a telephone survey. On average, maximum pain intensity as determined using an NRS was recorded as 9<i>.</i> 3 <i>±</i> 1<i>.</i> 1 prior to delta 9‐THC and 6<i>.</i> 1 <i>±</i> 2<i>.</i>1 thereafter, but without identification of the time period for assessment for change in pain. Data on HRQoL, disability, depression and drop‐out rates due to adverse events were not reported separately for people with fibromyalgia. About 25% of the total sample did not tolerate the treatment (<a href="./references#CD011694-bbs2-0076" title="WeberJ , SchleyM , CasuttM , GerberH , SchuepferG , RukwiedR , et al. Tetrahydrocannabinol (Delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: results of a multicenter survey. Anesthesiology Research and Practice2009;2009:pii: 827290.">Weber 2009</a>). In another study, 28 Spanish people with fibromyalgia who were herbal cannabis users and 28 non‐users, without differences in demographics and clinical variables, were compared. After two hours of cannabis use, there was a statistically significant reduction of pain and stiffness, enhancement of relaxation and an increase in somnolence and feeling of well‐being (all P values &lt; 0.001). The mental health component summary score of the 36‐item Short Form (SF‐36) was significantly higher in cannabis users than in non‐users. There were no significant differences in the other SF‐36 domains, or in the FIQ (<a href="./references#CD011694-bbs2-0018" title="FizJ , DuránM , CapellàD , CarbonellJ , FarréM . Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One2011;6:e18440.">Fiz 2011</a>). In one Canadian case series of a tertiary care pain centre, cannabinoids were being used by 13% of people with fibromyalgia, of whom 80% used herbal cannabis (marijuana). Current unstable mental illness, opioid drug‐seeking behaviour and male sex were all associated with herbal cannabis use. There was a trend for cannabinoid users to be unemployed and receiving disability payments (<a href="./references#CD011694-bbs2-0071" title="Ste-MariePA , FitzcharlesMA , GamsaA , WareMA , ShirY . Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care &amp; Research (Hoboken)2012;64:1202-8.">Ste‐Marie 2012</a>). In one survey of the US National Pain Foundation, over 1300 people with fibromyalgia rated marijuana more effective than Food and Drug Administration (FDA)‐approved duloxetine, milnacipran and pregabalin. The survey showed that only 8% of duloxetine, 10% of pregabalin and 10% of milnacipran users found the medication to be "very effective," while 60% of duloxetine, 61% of pregabalin and 68% of milnacipran users replied that the medications, "does not help at all." In contrast, 62% of marijuana users rated it very effective. Only 5% said it did not help at all (<a href="./references#CD011694-bbs2-0059" title="National Pain Foundation. Marijuana rated most effective for treating fibromyalgia, 2014. www.thenationalpainfoundation.org/pain-news.php (accessed 1 April 2015).">National Pain Foundation 2014</a>). </p> <p>The findings of this review regarding the most frequent adverse events associated with cannabinoids (drowsiness, dizziness, dry mouth) were in line with the findings of one systematic review of cannabinoids in chronic non‐cancer pain that included 18 RCTs with 766 participants (<a href="./references#CD011694-bbs2-0040" title="LynchME , CampbellF . Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. British Journal of Clinical Pharmacology2011;72:735-44.">Lynch 2011</a>). One Canadian case series point to low tolerability and poorer mental health and functionality for cannabinoid users with fibromyalgia (<a href="./references#CD011694-bbs2-0071" title="Ste-MariePA , FitzcharlesMA , GamsaA , WareMA , ShirY . Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care &amp; Research (Hoboken)2012;64:1202-8.">Ste‐Marie 2012</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011694-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/urn:x-wiley:14651858:media:CD011694:CD011694-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011694-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/image_n/nCD011694-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/image_t/tCD011694-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/full#CD011694-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/image_n/nCD011694-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011694-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/urn:x-wiley:14651858:media:CD011694:CD011694-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011694-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/image_n/nCD011694-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/image_t/tCD011694-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/full#CD011694-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/image_n/nCD011694-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011694-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/urn:x-wiley:14651858:media:CD011694:CD011694-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011694-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/image_n/nCD011694-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/image_t/tCD011694-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/full#CD011694-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011694.pub2/media/CDSR/CD011694/image_n/nCD011694-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011694.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011694-note-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011694-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011694-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011694-note-0008">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011694-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD011694-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011694-note-0007">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011694-note-0003">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011694\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011694\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011694\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011694\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011694\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011694.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011694.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011694.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011694.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011694.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717211010"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011694.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717211014"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011694.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db2640e9e9365',t:'MTc0MDcxNzIxMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 